Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Coherus Biosciences Inc Market Cap
From what 8 stock analysts predict, the share price for Coherus Biosciences Inc (CHRS) might increase by 813.46% in the next year. This is based on a 12-month average estimation for CHRS. Price targets go from $1.5 to $23. The majority of stock analysts believe CHRS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CHRS is a stock in Health Care which has been forecasted to be worth $9.5 as an average. On the higher end, the forecast price is $23 USD by from and on the lower end CHRS is forecasted to be $1.5 by Ashwani Verma from UBS.
These are the latest 20 analyst ratings of CHRS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ashwani Verma UBS | Neutral | $1.5 | Downgrade | Aug 16, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 5, 2024 |
| Colleen Kusy Baird | Outperform | $8 | Maintains | Jul 1, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | May 24, 2024 |
| Robyn Karnauskas Truist Securities | Buy | $7 | Maintains | May 13, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Maintains | May 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Maintains | Mar 20, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Mar 14, 2024 |
| Robyn Karnauskas Truist Securities | Buy | $8 | Maintains | Jan 23, 2024 |
| Colleen Kusy Baird | Outperform | $9 | Maintains | Jan 23, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Dec 27, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Dec 7, 2023 |
| Robyn Karnauskas Truist Securities | Buy | $12 | Reiterates | Nov 28, 2023 |
| Colleen Kusy Baird | Outperform | $11 | Initiates | Nov 17, 2023 |
| Jason McCarthy Maxim Group | Hold | Downgrade | Nov 8, 2023 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Maintains | Nov 7, 2023 |
| Balaji Prasad Barclays | Overweight | $7 | Maintains | Oct 23, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $20 | Reiterates | Sep 26, 2023 |
| Robyn Karnauskas Truist Securities | Buy | $20 | Reiterates | Sep 26, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $20 | Maintains | Aug 3, 2023 |
When did it IPO
2014
Staff Count
246
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Dennis M. Lanfear
Market Cap
$160.1M
In 2023, CHRS generated $257.2M in revenue, which was a increase of 21.89% from the previous year. This can be seen as a signal that CHRS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 13 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with strategic divestitures impacting its financial position post Q3 2024. UDENYCA drives most of CHRS's revenues, positioning it as its crown jewel with a 29% market share and strong payer coverage.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securities Michael Nedelcovych - TD Cowen Colleen Kusy - Robert W.
Thu, 08 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Thu, 27 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - – Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –
Thu, 30 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
